Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2019-07-15 09:22 am Sale | 13D | AXOVANT GENE THERAPIES LTD COM AXGT | VIKING GLOBAL INVESTORS LP | 0 0% | -105,952,381 (Position Closed) | View |
| 2019-07-12 4:59 pm Sale | 13D | MYOVANT SCIENCES LTD COM MYOV | VIKING GLOBAL INVESTORS LP | 0 0% | -40,765,599 (Position Closed) | View |
| 2019-07-12 4:57 pm Sale | 13D | ARBUTUS BIOPHARMA CORP ABUS | VIKING GLOBAL INVESTORS LP | 0 0% | -16,013,540 (Position Closed) | View |
| 2019-07-12 4:52 pm Sale | 13D | UROVANT SCIENCES LTD SHS UROV | VIKING GLOBAL INVESTORS LP | 0 0% | -22,703,669 (Position Closed) | View |
| 2019-07-08 4:46 pm Purchase | 13D | BRIDGEBIO PHARMA INC BBIO | VIKING GLOBAL INVESTORS LP | 26,620,991 22.1% | 26,620,991 (New Position) | View |
| 2019-06-14 5:12 pm Purchase | 13D | MYOVANT SCIENCES LTD COM MYOV | VIKING GLOBAL INVESTORS LP | 40,765,599 45.6% | 2,424,242 (+6.32%) | View |